Flying under the radar: the new wave of BCR–ABL inhibitors | Nature Reviews Drug Discovery
Inhibition of DDR1‐BCR signalling by nilotinib as a new therapeutic strategy for metastatic colorectal cancer | EMBO Molecular Medicine
Proposed mechanism of nilotinib in the regulation of pigmentation.... | Download Scientific Diagram
Anti-Alpha-Synuclein Therapies in Parkinson's Disease - Practical Neurology
Inhibition of DDR1‐BCR signalling by nilotinib as a new therapeutic strategy for metastatic colorectal cancer | EMBO Molecular Medicine
Current status of therapy for chronic myeloid leukemia: a review of drug development | Future Oncology
CML therapy : post-Gleevec® era - ppt download
Mode of action of imatinib. The phosphorylation of a substrate is shown... | Download Scientific Diagram
Evaluation of resistance to HIV-1 infection ex vivo of PBMCs isolated from patients with chronic myeloid leukemia treated with different tyrosine kinase inhibitors - ScienceDirect
Targeting kinases in Parkinson's disease: A mechanism shared by LRRK2, neurotrophins, exenatide, urate, nilotinib and lithium - Journal of the Neurological Sciences
Why I Do Buy Biotech | Seeking Alpha
An interesting commentary on the interpretation of the Nilotinib trial results – The Science of Parkinson's
Nilotinib induces apoptosis and autophagic cell death of activated hepatic stellate cells via inhibition of histone deacetylases - ScienceDirect
5MJC BCU 13: Tyrosine Kinases as Targets for Cancer Therapy | Research To Practice
Tyrosine Kinase Inhibitors in Leukemia and Cardiovascular Events | Arteriosclerosis, Thrombosis, and Vascular Biology
Nilotinib - Wikipedia
Chemical structures of the ATP competitors imatinib, nilotinib,... | Download Scientific Diagram
Imatinib - Wikipedia
Frontiers | Combination Therapies in Chronic Myeloid Leukemia for Potential Treatment-Free Remission: Focus on Leukemia Stem Cells and Immune Modulation | Oncology
Chronic Myeloid Leukemia - ppt video online download
Frontiers | BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia | Oncology
Third-line therapy for chronic myeloid leukemia: current status and future directions | Journal of Hematology & Oncology | Full Text
Haematological adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukaemia: A network meta‐analysis - Fachi - 2019 - British Journal of Clinical Pharmacology - Wiley Online Library
Enhanced in vivo targeting of estrogen receptor alpha signaling in murine mammary adenocarcinoma by nilotinib/rosuvastatin novel combination - ScienceDirect
Pharmacology of Drugs: Nilotinib
Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review | SpringerLink
